What is the appropriate antimicrobial therapy for enteric fever in adults and children?

Treatment for Enteric Fever

For enteric fever, azithromycin or ceftriaxone should be the first-line treatment in most settings, with fluoroquinolones reserved only for regions with documented susceptibility, which now excludes most of South Asia due to widespread resistance. 1

Recommended Treatment Algorithm

First-Line Options (Choose Based on Local Resistance Patterns):

Azithromycin is the preferred agent in areas with fluoroquinolone resistance (particularly South Asia):

• Lower clinical failure rates compared to fluoroquinolones (OR 0.48,95% CI 0.26-0.89) 1
• Shorter hospital stays by approximately 1 day 1
• Significantly lower relapse rates compared to ceftriaxone (OR 0.09,95% CI 0.01-0.70) 1, 2
• Maintains complete susceptibility across most regions 3

Ceftriaxone is equally effective as first-line therapy:

• May result in decreased clinical failure compared to azithromycin 1
• Faster fever clearance (0.52 days shorter) than azithromycin 1
• Complete susceptibility maintained throughout 2005-2014 in South Asian studies 4
• Essential for extensively drug-resistant (XDR) strains, often combined with azithromycin 5

Second-Line Options:

Fluoroquinolones (ciprofloxacin, gatifloxacin, ofloxacin) - Use ONLY if local susceptibility is confirmed:

• Nalidixic acid resistance increased from 18% to 100% for S. Paratyphi A and 67% to 82% for S. Typhi between 2007-2013 in South Asia 3
• Rising MICs correlate with increasing fever clearance times 4
• Should NOT be used empirically in South Asia 6

Cefixime (oral cephalosporin):

• May have higher clinical failure rates than fluoroquinolones (RR 13.39) 1
• Longer time to defervescence (1.74 days longer than fluoroquinolones) 7
• Consider only when parenteral therapy is not feasible and susceptibility is confirmed

Critical Pitfalls to Avoid

1. Do not use fluoroquinolones empirically in South Asia - The WHO 2012 guidelines recommending fluoroquinolones as first-line are outdated 1. Resistance patterns have fundamentally changed since those recommendations were issued 4.

2. Recognize XDR typhoid - Particularly from Pakistan, these strains require azithromycin and/or meropenem 5. Standard cephalosporins alone may be insufficient.

3. Old first-line agents (chloramphenicol, ampicillin, trimethoprim-sulfamethoxazole) - Multidrug resistance remains stable but these should not be first-line choices despite some areas showing re-emerging susceptibility 3.

Treatment Duration and Monitoring

• Fever typically resolves within 3-7 days of appropriate therapy 6
• Failure to respond within 72 hours should prompt reassessment of antimicrobial choice based on culture and susceptibility results
• Blood or bone marrow culture remain the reference standard despite low sensitivity 6

Evidence Quality Considerations

The strongest recent evidence 4 from 2092 patients demonstrates that fluoroquinolone MICs have risen significantly since 2005, directly correlating with treatment failure. This contradicts older WHO guidelines 1 that still recommend fluoroquinolones first-line. The 2024 guideline synthesis 1 acknowledges this discrepancy, noting that "studies were old and resistance patterns have changed over time."

The combination therapy approach (azithromycin plus cefixime) is currently under investigation in the ACT-SA trial 5, targeting both intracellular and extracellular bacteria, which may become the future standard for complicated or resistant cases.